Please assess the completion status of the following clinical trial:

Trial Title: Minimize Menorrhagia in Women With Von Willebrand Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult females 13-45 years of age.~2. Mild or moderate von Willebrand disease (VWF:RCo \<0.50 IU/ml, normal multimers, past bleeding)~3. Menorrhagia defined as PBAC \>100 in at least one of the last two menstrual cycles.~4. Regular menses, at least every 21-35 days.~5. Willingness to have blood drawn~6. No prior history of an allergic reaction or anaphylaxis to rVWF or TA.~7. Willingness to avoid aspirin (ASA) and nonsteroidal anti-inflammatory agents (NSAIDS) during the study.~8. Willingness to comply with randomization to rVWF or TA study arms.~9. Willingness to keep a personal diary of menorrhagia bleeding frequency duration and severity by pictorial blood assessment chart, and any drugs or hemostatic agents taken.~10. Willingness to make 4 visits and undergo blood sampling for coagulation studies, and accept randomization of two therapies for each of four consecutive menstrual cycles, including an end-of-study visit.~11. Willingness to use double-barrier method of contraception during the study.~Exclusion Criteria:~1. Any bleeding disorder other than von Willebrand disease; or past thrombotic disease~2. Pregnant or lactating, or use of hormones (other than progesterone-only), or combined oral contraceptives, and contraceptive implants in past 3 months.~3. Platelet count \< 100,000/ul.~4. Use of immunomodulatory or experimental drugs.~5. Surgery within the past 8 weeks.~6. Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs.~7. Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing VWF within 5 days of study.~8. Inability to comply with study requirements.~9. Hypothyroidism as defined by elevated TSH.~10. Iron deficiency as defined by low serum ferritin, unless iron replacement has been initiated.~11. History of renal disease

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Group I (Type: ACTIVE_COMPARATOR): Subjects randomized to Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
- Group II (Type: ACTIVE_COMPARATOR): Group II will receive Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues